SAN DIEGO, May 5, 2014 (GLOBE NEWSWIRE) -- Angstrom Pharmaceuticals, Inc. (“Angstrom” or the “Company”) announced today the activation of a clinical trial titled, “A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients with Chronic Lymphocytic Leukemia.”
Help employers find you! Check out all the jobs and post your resume.
